Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

What's fueling the biotech engine—2008

Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1
Figure 2: Top companies that comprise the majority of sales of biologic drugs in 2008.
Figure 3: Top nine categories of biologic drugs in terms of US sales in 2008.
Figure 4: Trends in US sales of mAbs.
Figure 5: Trends in US sales of growth factors.
Figure 6: Trends in US sales of recombinant hormones.
Figure 7: US sales of cytokines, therapeutic enzymes and recombinant vaccines.
Figure 8: US sales of blood factors and anticoagulants.

References

  1. 1

    Aggarwal, S. Nat. Biotechnol. 26, 1227–1233 (2008).

    CAS  Article  Google Scholar 

  2. 2

    Anonymous. IMS Health Reports U.S. Prescription Sales Grew 1.3 Percent in 2008 to $291 Billion. IMS, Norwalk, CT, USA, March 19, 2009. http://www.imshealth.com/portal/site/imshealth/ menuitem.a46c6d4df3db4b3d88f611019418c22a/ ?vgnextoid=078ce5b87da10210VgnVCM100000ed152ca2RCRD& vgnextchannel=41a67900b55a5110VgnVCM10000071812ca2 RCRD&vgnextfmt=default

  3. 3

    Aggarwal, S. Nat. Biotechnol. 25, 1097–1104 (2007).

    CAS  Article  Google Scholar 

  4. 4

    Spaide, R.F. et al. Retina 26, 383–390 (2006).

    PubMed  Google Scholar 

  5. 5

    Kenneth, R.C. et al. Blood 113, 4834–4840 (2009).

    Article  Google Scholar 

  6. 6

    Leavitt, M.O. A Design for a Bundled End Stage Renal Disease Prospective Payment System. Report to Congress, 2008.http://www.cms.hhs.gov/ESRDGeneralInformation/downloads/ ESRDReportToCongress.pdf

    Google Scholar 

  7. 7

    United States Government Accountability Office Report to Congressional Committees. Bundling Medicare's Payment for Drugs with Payment for All ESRD Services Would Promote Efficiency and Clinical Flexibility (US GAO, Washington, DC, USA, 2006) http://www.gao.gov/products/GAO-07-77

  8. 8

    Jonasson, J.M. et al. Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden. Diabetologia. 52, 1745–1754 (2009).

    CAS  Article  Google Scholar 

  9. 9

    Rosenstock, J. et al. Diabetologia 52, 1971–1973 (2009).

    CAS  Article  Google Scholar 

  10. 10

    Cohen, J. et al. Oral fingolimod (FTY720) versus interferon β-1a in relapsing-remitting multiple sclerosis: results from a Phase III study (TRANSFORMS). Slide deck associated with oral presentation at the American Academy of Neurology Annual Meeting 2009, Seattle, April 25–May 2, 2009.

    Google Scholar 

  11. 11

    Babbit, B., Nick, C. & Aggarwal, S. Product Development Strategies for Follow-on Biologics Part II, Windhover, Norwalk, CT, April 23, 2009. http://www.windhover.com/ezine/html/ac0409-lp.htm

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Saurabh Aggarwal.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Aggarwal, S. What's fueling the biotech engine—2008. Nat Biotechnol 27, 987–993 (2009). https://doi.org/10.1038/nbt1109-987

Download citation

Further reading

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing